Modifiable Risk Factors for Cognitive Dysfunction in Patients With Coronary Heart Disease
Association Between Modifiable Risk Factors and Cognitive Function in Patients With Coronary Heart Disease
1 other identifier
observational
2,352
1 country
1
Brief Summary
This prospective observational study aims to investigate the association between risk factors and cognitive function in patients with coronary heart disease (CHD), and to explore the underlying mechanisms involving metabolic parameters and multimodal imaging features. A total of 2,352 participants will be enrolled from Beijing Anzhen Hospital, Capital Medical University, China. Eligible participants are adults (≥18 years) with confirmed CHD who undergo systematic neuropsychological assessment during hospitalization. Comprehensive assessments include cognitive function tests (MMSE, MoCA, BCAT, AD8), metabolic evaluations (fasting glucose, insulin, HbA1c, ceramides), coronary computed tomography angiography (CCTA), cardiac magnetic resonance (CMR), sleep respiratory monitoring, and frailty and psychological assessments.The primary outcome is cognitive impairment. The study will identify potential risk factors and provide insights into early identification and personalized intervention strategies for cognitive decline in CHD patients.This study is led by the National Clinical Research Center for Cardiovascular Diseases and invited to be carried out by several Chinese centers including Beijing Anzhen Hospital.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jun 2025
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 30, 2025
CompletedFirst Submitted
Initial submission to the registry
June 15, 2026
CompletedFirst Posted
Study publicly available on registry
June 18, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2031
ExpectedStudy Completion
Last participant's last visit for all outcomes
May 1, 2031
July 15, 2026
July 1, 2025
5.8 years
June 15, 2026
July 14, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Cognitive impairment
Cognitive impairment in patients with coronary heart disease, defined by standardized neuropsychological assessments including the Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), Brief Cognitive Assessment Tool (BCAT), and Alzheimer's Disease 8-Item Screening Questionnaire (AD8), evaluated as a binary outcome (presence or absence of cognitive impairment).
2026-2031
Study Arms (1)
CHD Patients with Cognitive Assessment Cohort
Eligibility Criteria
This study population consists of 2,352 adult patients aged 18 years and older with a confirmed diagnosis of coronary heart disease (CHD) who are recruited at Beijing Anzhen Hospital, Capital Medical University. Eligible participants have documented coronary artery stenosis ≥50% on angiography or CTA, a prior CHD diagnosis with medical/interventional/surgical treatment, or objective evidence of myocardial ischemia; they must be able to complete standardized neuropsychological cognitive assessments, undergo metabolic testing and cardiac imaging (CCTA/CMR), and provide written informed consent. Patients are excluded if they have pre-existing dementia, a history of stroke or other cognitive-impairing central nervous system diseases, severe psychiatric disorders, or are pregnant/breastfeeding. This is a non-interventional, observational cohort undergoing only routine clinical evaluations to explore modifiable risk factors for cognitive impairment in CHD patients.
You may qualify if:
- Age ≥ 18 years
- Diagnosis of coronary heart disease (meeting at least one of the following):
- Coronary angiography or coronary CTA showing ≥50% stenosis in ≥1 major coronary artery;
- Established diagnosis of coronary heart disease with prior medical, interventional, or surgical treatment;
- Objective evidence of myocardial ischemia or typical clinical symptoms
- Completion of standardized neuropsychological assessment during hospitalization
- Completion of metabolic marker evaluation (fasting glucose, insulin, HbA1c, etc.) and agreement to undergo relevant imaging and functional assessments
- Provision of signed written informed consent
You may not qualify if:
- Previously diagnosed dementia.
- History of stroke, cerebral hemorrhage, or other central nervous system diseases known to cause cognitive impairment.
- Severe psychiatric disorders (e.g., schizophrenia, bipolar disorder).
- Pregnancy or breastfeeding.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Beijing Anzhen Hospital
Beijing, China, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- OTHER
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Chief Physician
Study Record Dates
First Submitted
June 15, 2026
First Posted
June 18, 2026
Study Start
June 30, 2025
Primary Completion (Estimated)
May 1, 2031
Study Completion (Estimated)
May 1, 2031
Last Updated
July 15, 2026
Record last verified: 2025-07
Data Sharing
- IPD Sharing
- Will not share